Splenic Marginal Zone Lymphoma — Trials

Splenic Marginal Zone Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

135 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 9%
Top sponsor: City of Hope Medical Center
Termination share: 38.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 51–58 of 58 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00089076	MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma	terminated	Phase 1 / Phase 2	18	National Cancer Institute (NCI)NIH	1	May 30, 2014	clinicaltrials
NCT00054639	Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma	completed	Phase 2	48	National Cancer Institute (NCI)NIH	1	May 28, 2014	clinicaltrials